Biostar Pharmaceuticals Profit Margin

The latest profit margin for BSPM is 98.6% as of September 2017. That compares with -842.53% in the prior-year period — up 111.7% year over year. That is above the sector sector average of 13.78%. Investors often review this figure alongside Biostar Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, BSPM's profit margin moved from -842.53% to 98.6% — a 111.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Biostar Pharmaceuticals's valuation or profitability profile.

Against its sector companies, BSPM currently prints 98.6% for profit margin, while the sector average sits near 13.78%. That is roughly 615.7% above the sector mean. Large gaps often invite a closer look at Biostar Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Biostar Pharmaceuticals converts resources into returns. At 98.6%, BSPM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -842.53% in the prior-year period — up 111.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BSPM's profit margin (98.6%), review year-over-year change from -842.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.